Established in 1998, Cobram Estate is Australia’s most awarded Extra Virgin Olive Oil. We produce the highest quality Extra Virgin Olive Oil packed with antioxidants and healthy fats for proven health benefits. At Cobram Estate our Extra Virgin Olive Oil is made from premium olive varieties grown in our Australian groves, picked at optimum ripeness, and first cold pressed within 4-6 hours of harvest, guaranteeing high quality and healthy oil. For more information on the health benefits of Cobram Estate Extra Virgin Olive Oil visit www.health.cobramestate.com.au
Novartis Australia and New Zealand
Novartis is improving the lives of more than 2.5 million patients across Australia and New Zealand through our medicines.
By partnering with the healthcare system we are working for patients to address their needs, and we are committed to accelerating patient access to life saving treatments and associated healthcare.
We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich research pipeline has 200+ projects in development. We are transforming how clinical trials are run to increase patients’ access to our industry-leading clinical trials footprint in Australia.
Founded in 1983, Technogym is a world-leading brand in fitness, wellness, sport, and health. Technogym offers a complete Ecosystem of connected smart equipment, digital services, on-demand training experiences and apps that enable each user to access a fully personalized workout experience anywhere and anytime: at home, at the gym and on-the-go. With over 2,500 employees Technogym is present in over 100 countries. More than 70 million people train with Technogym equipment in 100,000 Wellness centers and 500,000 private homes in the world. Technogym has been appointed for the tenth time as the Official Supplier of the Milano Cortina 2026 Winter Olympic and Paralympic Games and is the brand of choice for training champions around the world
Established in 1991 and headquartered in Sydney, Amgen Australia works to further the company’s global efforts to transform the promise of biology and technology into therapies that restore health and save lives. Hundreds of thousands of Australians use one of Amgen’s products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia’s leading healthcare, academic, research, government and patient organisations.
Contact details:
Website: https://www.amgen.com.au/
Email: ausinfo@amgen.com
We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas – respiratory, immunology and inflammation; oncology; HIV; and infectious diseases – to impact health at scale. We operate responsibly for all our stakeholders.
Specialty Medicines: Our specialty medicines prevent and treat
diseases, from HIV, cancer and asthma to autoimmune diseases like lupus.
Vaccines: Our broad vaccines portfolio targets infectious diseases at every stage of life.
General Medicines: From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products.
Cardihab is Australia's leading digital therapeutic for cardiac rehabilitation and the only TGA-registered Class IIa medical device purpose-built to make evidence-based cardiac rehabilitation accessible to patients, regardless of where they live. With ISO 13485 and ISO 27001 certification, our infrastructure provides robust quality systems and standards that our customers depend on.
Cardihab partners with 85% of private health insurers, public health services, and clinical networks to deliver structured, guideline-aligned cardiac rehabilitation programs remotely, supported by clinical oversight, medication adherence and coaching, program monitoring, exercise prescription, and multidisciplinary care coordination.
With multiple peer-reviewed clinical evidence publications, and over a decade of real-world implementation experience, 59% uptake, 91% completion, improved survival, quality of life and health economic data, Cardihab is closing the cardiac rehabilitation participation gap.